Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)

Funding Opportunity PAR-18-332 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase l trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/therapeutics/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental drugs or biologics), or computational algorithms. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding